Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Thymopentin (TP-5) vs Thymalin — Peptide Comparison

At a Glance Quickcomparison Dose Range Thymopentin (TP-5) 1–2 mg Thymalin 5–10 mg Frequency Once daily Administration Subcutaneous injection Intramuscular injection Cycle Length 4-6 weeks Onset Speed Moderate (1-2 weeks) Evidence Level Moderate human trials (P

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

At a Glance

Quickcomparison

Dose Range

Thymopentin (TP-5)

1–2 mg

Thymalin

5–10 mg

Frequency

Once daily

Administration

Subcutaneous injection

Intramuscular injection

Cycle Length

4-6 weeks

Onset Speed

Moderate (1-2 weeks)

Evidence Level

Moderate human trials (Phase 1-2)

Limited human trials

Efficacy

Benefitratings

Immune Enhancement

Cardiovascular Support

Post-Recovery Support

Immune Restoration

Longevity Support

Disease Prevention

Technical Data

Compoundspecifications

Molecular Formula

C30H49N9O9

Molecular Weight

679.8

Half-Life

30 seconds to few minutes in plasma

Bioavailability

Sustained release via subcutaneous route

CAS Number

69558-55-0

Complex mixture; active dipeptide EW: C16H19N3O5

Polypeptide complex; components 250-1000 Da; active dipeptide EW ~321 Da

Not precisely characterized for complex; immune effects persist weeks post-administration

High via intramuscular or subcutaneous injection

63958-90-7

Protocols

Dosingtiers

standard

50 mg

Three times weekly

6 weeks to 48 weeks depending on indication

Dose used in controlled clinical trials, e.g. 50 mg SC three times weekly in HIV and atopic dermatitis studies [5].

advanced

50 mg by slow IV

Repeated injections (e.g. three times weekly)

Several weeks

Slow intravenous infusion was used in rheumatoid arthritis trials and may enhance in-vivo potency versus bolus dosing [5].

5-10 mg reconstituted in saline

5-10 day course, often repeated every 6 months

Reflects the Russian clinical course used in immune-restoration and gerontology protocols, typically 10 mg IM daily for 5-10 days [1].

10 mg

Up to 20 day course, repeated every 6 months

Subcutaneous administration is used in community practice at the same 10 mg daily dosing; longer 20-day courses are described for cyclical immune support [1].

Applications

Bestsuited for

Immune System Enhancement

Thymopentin directly increases T-cell function and promotes dendritic cell maturation, making it ideal for people seeking to boost immune response naturally

Cardiac Health Support

Clinical trials show thymopentin improves ejection fraction and exercise capacity in elderly heart failure patients while enhancing immune markers

Post-Surgery Recovery

Helps restore immune function after major surgery and protects important immune responses during recovery period

Aging Adults Seeking Immune Support

Thymalin is especially valuable for people over 55 whose thymus gland has naturally shrunk with age. By stimulating thymic function, it helps restore the immune training center that your body relies on to fight infections and stay healthy.

Longevity and Anti-Aging Protocols

Clinical studies tracking patients for 6-8 years showed Thymalin reduced mortality by 2.0-2.1-fold. Combined with Epitalon, the mortality reduction reached an impressive 4.1-fold, making this combination one of the most studied longevity peptide protocols.

Seasonal Illness Prevention

Research shows Thymalin cuts respiratory infection rates by 2.0-2.4-fold. A short 10-day course before cold and flu season can significantly boost your immune defenses for months afterward.

Safety Profile

Sideeffects

Common

Local injection site reaction

Mild fatigue

Transient fever

Uncommon

Muscle aches

Mild headache

Serious

Allergic reaction

No side effects in most patients

Mild injection site reaction

Transient low-grade fever

Mild flu-like symptoms

Temporary headache

Severe allergic reaction

Research Status

Safety& evidence

FDA Status

Research compound

Safety Overview

Thymopentin is well-tolerated with minimal side effects reported in clinical trials. Most adverse events are mild and local. No serious safety concerns have emerged from decades of clinical use in China and Europe.

Contraindications

xPregnancy and breastfeeding

xActive malignancy (without medical supervision)

xSevere immunosuppression

xHypersensitivity to peptide medications

Thymalin has an excellent safety profile based on over 40 years of clinical use in Russia. Most patients experience zero side effects, and the peptide complex has been described as 'practically non-toxic' in research literature. It has been used safely in thousands of patients, including elderly populations over extended periods.

xActive thymic tumors or malignancies

xKnown hypersensitivity to animal-derived peptide products

xPregnancy and breastfeeding (insufficient safety data)

xSevere uncontrolled autoimmune disease without medical supervision

Decision Guide

Which isright for you?

Choose Thymopentin (TP-5) if...

Immune system strengthening

Recovering from illness or surgery

Managing autoimmune conditions

Supporting cardiac health in elderly patients

Choose Thymalin if...

Immune system restoration in aging adults

Longevity and healthy aging support

Reducing infection frequency and severity

Multi-system health optimization

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Research context

Read sources and limitations before applying a claim.

Safety& evidence

FDA Status Research compound Safety Overview Immunoxel has demonstrated a favorable safety profile across multiple clinical trials involving hundreds of patients with TB and TB/HIV coinfection. No serious adverse events have been reported in published studies. It is approved by Ukraine's Ministry of Health and has been used clinically since the late 1980s. Side effects are generally mild and gastrointestinal in nature. Contraindications xKnown hypersensitivity to any of the plant ingredients in the formulation xPregnancy and breastfeeding (insufficient safety data) xSevere liver disease (contains alcohol-based extract) xUse as sole therapy for TB or HIV (must be combined with standard treatment) Imunofan (Iletin-alpha, a synthetic tetrapeptide) demonstrates good tolerability in Russian clinical practice spanning 20+ years with oral and parenteral administration. Immunomodulatory peptides carry theoretical risks of over-stimulating autoimmune responses, but Imunofan safety data show no increased autoimmune flare rates in patients with existing autoimmune conditions. Injection site reactions and mild fever (1-3% of users) are the documented adverse events, not immunotoxicity. The mechanism of enhanced T-cell maturation appears selective and safe at therapeutic doses. xKnown hypersensitivity to imunofan or excipients xPregnancy complicated by Rh-conflict (contraindicated) xChildren under 2 years of age xSevere allergic conditions in acute exacerbation Decision Guide

Source: peptideinitiative.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →